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Wound healing, angiogenesis, and hair follicle maintenance are often impaired in the skin of diabetic patients,
but the pathogenesis has not been well understood. Here, we report that circulation levels of kallistatin, a
member of the serine proteinase inhibitor (SERPIN) superfamily with antiangiogenic activities, were elevated in
type 2 diabetic patients with diabetic vascular complications. To test the hypothesis that elevated kallistatin levels
could contribute to a wound-healing deficiency via the inhibition of Wnt/b-catenin signaling, we generated
kallistatin-transgenic (KS-TG) mice. KS-TG mice had reduced cutaneous hair-follicle density, microvascular density,
and panniculus adiposus layer thickness, as well as altered skin microvascular hemodynamics and delayed
cutaneous wound healing. Using Wnt reporter mice, our results showed that Wnt/b-catenin signaling is
suppressed in the dermal endothelium and hair follicles in KS-TG mice. Lithium, a known activator of b-catenin
via inhibition of glycogen synthase kinase-3b, reversed the inhibition of Wnt/b-catenin signaling by kallistatin and
rescued the wound-healing deficiency in KS-TG mice. These observations suggest that elevated circulating
antiangiogenic serpins in diabetic patients may contribute to impaired wound healing through inhibition of Wnt/
b-catenin signaling. Activation of Wnt/b-catenin signaling, at a level downstream of Wnt receptors, may
ameliorate the wound-healing deficiency in diabetic patients.
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INTRODUCTION
Globally, every 30 seconds, a limb is amputated owing to
pathologic complications associated with diabetes mellitus
(Tseng, 2006; Rajamani et al., 2009; Margolis et al., 2011).
There is a strong clinical need to identify biomarkers or
therapeutic targets in the circulation and skin that modulate
skin maintenance and repair in diabetes.
In humans, 20 extracellular serine proteinase inhibitors
(SERPINs) comprise B10% of proteins by mass in the human
circulation (Irving et al., 2000; Goettig et al., 2010). Serpins
a1-antitrypsin (SERPINA1), pigment epithelium–derived factor
(SERPINF1), and kallistatin (SERPINA4) have displayed anti-
angiogenic activities (Dawson et al., 1999; McMahon et al.,
2001; Miao et al., 2002). Recently, we have shown that
kallistatin binds with low-density lipoprotein receptor–related
protein 6 (LRP6), an essential coreceptor of the canonical Wnt
pathway, and suppresses the activation of Wnt signaling by
Wnt ligands (Liu et al., 2013). Here, we explore the concept
that kallistatin regulates skin hair follicle development and
wound healing through interactions with the canonical Wnt
signaling pathway.
Canonical Wnt signaling in adult tissues upregulates the
expression of direct T-cell factor (TCF)/lymphoid enhancer
factor-1 target genes that modulate hair follicle growth
(DasGupta and Fuchs, 1999), cell proliferation (He et al.,
1998), and angiogenesis (Zhang et al., 2001). Wnt ligands,
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such as Wnt3a, bind to a coreceptor complex consisting of
frizzled receptors and LRP6, causing phosphorylation of LRP6
and recruitment of a degradation complex consisting of casein
kinase 1, glycogen synthase kinase-3b, and adenopolyposis
coli protein. In the absence of Wnt ligand, this kinase complex
phosphorylates b-catenin, leading to degradation of b-catenin
in the cytoplasm (MacDonald et al., 2009). Phosphorylation
and degradation of b-catenin is prevented when Wnt ligands
activate the pathway, and the stabilized b-catenin translocates
to the nucleus and dimerizes with the TCF–Groucho complex,
activating the transcription of corresponding direct target
genes. Canonical Wnt signaling is crucial for development
and has key roles in cancer progression (MacDonald et al.,
2009); yet, its role in wound healing has only recently been
studied (Fathke et al., 2006; Wu et al., 2011; Whyte et al.,
2012, 2013). Although Wnt signaling has been shown to
promote angiogenesis (Parmalee and Kitajewski, 2008;
Zerlin et al., 2008; Barcelos et al., 2009; Chen et al., 2009;
Phng et al., 2009; Dejana, 2010; Zhang and Ma, 2010;
Chen et al., 2011) and be essential for the morphogenesis
of hair follicles (Ito et al., 2007; Enshell-Seijffers et al.,
2010), the role of antiangiogenic serpins in modulating
Wnt signaling and wound healing in adult skin has not
been investigated. We undertook this study to explore the
role of kallistatin in modulation of wound healing and
identified a potential pharmacological rescue strategy to
attenuate the negative effects of antiangiogenic serpins in
wound healing.
RESULTS
Elevation of serum kallistatin levels in type 2 diabetic patients
with vascular complications
We analyzed kallistatin levels in the sera of healthy indivi-
duals and type 2 diabetic patients with or without clinically
evident diabetes-related vascular complications (Supplemen-
tary Table S1 online). In diabetic patients with complications,
87.5% of patients had microvascular complications, including
46.9% with peripheral neuropathy (Supplementary Table S1
online). Circulating kallistatin levels differed significantly
across the three subject groups (Figure 1). Kallistatin levels
were significantly higher in the type 2 diabetic patients with
vascular complications compared with nondiabetic control
subjects and diabetic patients without complications (Figure 1).
Kallistatin levels in diabetic patients showed correlations with
various clinical parameters related to vascular health, includ-
ing HbA1c, albumin-to-creatinine ratio, large-artery elasticity,
and small-artery elasticity (Supplementary Table S2 online).
Reduced hair-follicle density and skin microvascular density in
kallistatin-transgenic (KS-TG) mice
To understand the impacts of elevated kallistatin levels, we
generated KS-TG mice overexpressing and secreting human
kallistatin into the circulation and tissues (Supplementary
Figure S1a and b online). Circulating levels of endogenous
mouse kallistatin (SERPINA3C) were approximately 1mgml 1
in wild-type (WT) mice (Supplementary Figure S1c online),
whereas KS-TG mice had circulating levels of kallistatin at
5mgml 1 (Supplementary Figure S1d online). The increase of
serum levels of human kallistatin in KS-TG mice were
comparable to the fold increase of kallistatin in diabetic
patients with vascular complications. The elevated kallistatin
levels were detected in the skin of KS-TG mice at sufficient
amounts for studying a potential skin phenotype (Supple-
mentary Figure S1d online).
In vitro tissue kallikrein activity assays showed that KS-TG
mice had no detectable change in tissue kallikrein activity in
wounded skin or serum, compared with the WT mice
(Figure 3j and Supplementary Figure S1e online, respectively).
Comparing the amino-acid sequence of human kallistatin
(SERPINA4) with endogenous mouse kallistatin (SERPINA3C)
revealed that the sequence of the reactive center loop of
human kallistatin that interacts with and is cleaved by tissue
kallikrein is not identical to the sequence in mouse kallistatin
(Supplementary Figure S1f online), suggesting that human
kallistatin probably does not significantly impact the activity
of mouse tissue kallikrein.
Newborn KS-TG mice at postnatal day 0 (P0) had reduced
hair-follicle density compared with WT littermates (Figure 2a
and b; quantification in Figure 2i). Skin with telogen-phase
follicles in 3-month-old KS-TG mice showed significantly
decreased dorsal skin thickness (Figure 2c and d; quantifica-
tion in Figure 2k) and reduced hair-follicle density (Figure 2j).
Furthermore, as seen after synchronized induction of anagen
by depilation, induction of anagen-phase hair follicles
was attenuated in KS-TG mice relative to WT littermates
(Supplementary Figure S4 online). The decrease in 3-month-
old KS-TG mouse skin thickness was largely because of
a decrease in the thickness and cell population in the
panniculus adiposus (PA) layer, with nuclei numbers in the
dermis and panniculus carnosus layers being similar
(Figure 2e, f and l). The microvascular density in the skin of
KS-TG mice was significantly reduced (Figure 2g and h;
quantification in Figure 2m).
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Figure 1. Elevation of serum kallistatin (KS) levels in type 2 diabetic patients
with vascular complications of diabetes. Nondiabetic subjects (N¼ 45),
diabetic patients without vascular complications (DM w/o Cx, N¼ 36), and
diabetic patients with vascular complications (DM w/Cx, N¼44).
Mean±SEM, analysis of variance: P¼ 0.004, F¼ 5.626. Post hoc analysis
group-versus-group comparison indicated with bars. *Po0.05, **Po0.01.
NS, not significant.
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Kallistatin overexpression impairs skin hyperemic response to
ischemia
Pressure to the skin causes local ischemia. Upon release of
pressure, blood flow increases immediately, peaks and rapidly
stabilizes due to vascular reactivity (Tur et al., 1991). We
measured skin blood flow after standardized local ischemia in
adult WT and KS-TG mice (Figure 2n and o). WT skin blood
flow dynamics appeared as expected, with a sharp rise and
rapid return to baseline (Figure 2n). KS-TG mice, however,
had a blunted response above both baseline levels and
ischemia levels (Figure 2o; quantified in Figure 2p and q)
and had a delay in returning to baseline (Figure 2o).
KS-TG mice have delayed skin wound repair
Skin wound-healing assay demonstrated that wound closure
in KS-TG mice lagged behind WT littermates (Figure 3a).
Vascular density in the wound area was reduced in KS-TG
mice compared to WT mice at day 7 of wound healing, a peak
phase of endothelial cell proliferation during wound healing
(Nissen et al., 1998; Figure 3d, e, h, and i). There was no
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Figure 2. Kallistatin (KS) affects skin structure and function. (a–d) Hematoxylin and eosin, dorsal skin; (a, b) newborn postnatal day 0 (P0) wild-type (WT) and
kallistatin-transgenic (KS-TG) littermates, scale bar¼ 100mm; (c, d) 3-month-old littermates, scale bar¼ 500mm. (e, f) 4,6-Diamidino-2-phenylindole (DAPI)
staining; dotted lines indicate boundaries of the skin dermis, panniculus adiposus (PA), and panniculus carnosus (PC) layers; scale bar¼500mm. (g, h) FITC-anti-
CD31 antibody, scale bar¼ 50mm. (i, j) Hair-follicle density at P0 (i) and 3 months (j); (k) skin thickness; (l) nuclei between dotted lines in PC, PA, dermis (D);
(m) microvascular density. (n, o) Laser Doppler flowmetry in hindlimb skin, (n) WT and (o) KS-TG mice. (p, q) Hyperemic responses. N¼5 or45 in all analyses
with multiple sections/tissues per analysis. Mean±SEM, *Po0.05, **Po0.01, ***Po0.001. AU, arbitrary fluorescence units.
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difference in tissue kallikrein activity in wounds at day 7
(Figure 3j). Vascular density in wound beds at day 7 was
significantly decreased in KS-TG mice (Figure 3k). The
expression of vegf-a was significantly lower at both the mRNA
and protein levels in KS-TG mice versus WT mice during day
7 of wound healing (Figure 3l and m).
Kallistatin overexpression exacerbates wound-healing delay in
diabetic mice
Ins2akita mice represent a model of diabetes caused by an
insulin 2 gene mutation (Wang et al., 1999). Although KS-TG
mice and Ins2akita mice (3 months old) alone showed mild
delays in skin wound healing, Ins2akita  KS-TG mice had the
slowest wound healing rate of all groups (Figure 3n). Although
having thinner skin than WT, Ins2akita mice had better
angiogenic responses in wounds compared with Ins2akita 
KS-TG mice, at the age of 3 months (Figure 3o and p are
resting skin; Figure 3q and r are wounds; quantification in
Figure 3s).
KS-TG mice have reduced activation of Wnt/TCF/b-catenin
signaling in skin and wounds
We examined whether kallistatin overexpression affects Wnt/
TCF/b-catenin signaling in the skin by crossing KS-TG mice
with Wnt/TCF/b-catenin-reporter BAT-gal mice, which express
the b-galactosidase reporter gene under the control of a
promoter containing TCF/b-catenin-binding sites. 5-Bromo-4-
chloro-3-indolyl b-D-galactopyranoside staining indicated that
Wnt signaling was activated in the periphery of the wounded
skin (Figure 4a and b) and in cells that had an endothelial-like
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Figure 3. Kallistatin (KS) delays wound closure and inhibits wound angiogenesis. (a) Wound-healing rate (3-month-old male littermates). (b, c, f, g) Images of
representative wounds. (d, h) Hematoxylin and eosin, wound bed at day 7, scale bar¼50mm; (e, i) CD31, wound beds; (j) normalized tissue kallikrein activity in
wounds; (k) wound vascular area; (l) vegf-a mRNA levels in wounds; (m) VEGF-A in wound homogenates; (n) wound areas in 3-month-old male mice; (o, p)
CD31þ cells in resting skin in Ins2akita and Ins2akita  kallistatin-transgenic (KS-TG) mice; (q, r) CD31þ endothelial cells, wounded skin, Ins2akita and Ins2akita 
KS-TG mice. Scale bar (o–r)¼50mm. (s) CD31þ area. Mean±SEM, N¼5 or45 in all analyses with multiple sections/tissues per analysis, *Po0.05, **Po0.01,
***Po0.001. AU, arbitrary fluorescence units.
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morphology and were co-stained with CD31 (Figure 4c and d)
in the wound beds and hair follicles of BAT-gal mice. In the
wounded Wnt reporter mice, the number of hair follicles in
the immediate periphery of the wound with Wnt reporter
activity was significantly higher than in resting skin (Figure 4e).
The resting skin of BAT-gal mice had more than 25% of the
total population of hair follicles with Wnt activation, whereas
resting skin of BAT-gal  KS-TG mice had o10% of hair
follicles with Wnt signaling activation (Figure 4e). During the
proliferative phase of wound healing, BAT-gal mice had over
45% of Wnt-activated hair follicles adjacent to the wound
area, whereas BAT-gal  KS-TG mice had o10% activation
(Figure 4e). In wound beds in the proliferative stage, BAT-gal
mice had higher densities of cells with active Wnt signaling
(Figure 4h), and these cells were associated with CD31 in
wound beds, compared with BAT-gal  KS-TG mice
(Figure 4i; quantification in Figure 4j).
Kallistatin inhibits Wnt/b-catenin signaling in primary human
dermal microvascular endothelial cells
To dissect the effect of kallistatin on endothelial Wnt signaling,
we treated primary human dermal microvascular endothelial
cells (HDMVECs) with 30% Wnt3a-conditioned medium
(WCM) or with L-cell-conditioned medium (LCM) as control.
In an in vitro angiogenesis assay, kallistatin reduced the
WCM-induced tube and branch formation from HDMVECs
after a 12hour treatment (Figure 5a–c). WCM stimulated
HDMVEC proliferation over 72hours, compared with LCM
control (Figure 5d). Purified kallistatin inhibited WCM-
induced proliferation of the dermal microvascular endothelial
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cells, compared with BSA control (Figure 5d). Kallistatin
reduced Wnt3a-induced phosphorylation of LRP6, an essential
coreceptor of canonical Wnt signaling, and levels of non-
phosphorylated b-catenin in HDMVECs, suggesting an inhibi-
tory effect on Wnt signaling in endothelial cells (Figure 5e).
To assess kallistatin’s effect on Wnt3a/TCF/b-catenin-depen-
dent transcription in HDMVECs, we delivered vectors via
lentivirus for TCF/b-catenin-driven luciferase and constitu-
tively expressed Renilla luciferase. Luciferase assay revealed
that HDMVECs harbor the endogenous machinery for cano-
nical Wnt signaling and respond to Wnt3a ligand in WCM
versus LCM (Figure 5f). Furthermore, kallistatin dose depen-
dently reduced the transcriptional activity of b-catenin in
HDMVECs (Figure 5f). Expression of a direct angiogenic
Wnt/TCF/b-catenin target gene, vegf-a, was shown to be
upregulated in HDMVECs by WCM and downregulated by
kallistatin (Figure 5g). Taken together, these data support that
kallistatin impairs dermal angiogenesis, at least in part, by
inhibition of canonical Wnt/TCF/b-catenin signaling in skin
endothelial cells.
Lithium attenuates the effects of kallistatin on skin angiogenesis
and wound healing
To confirm that the effect of kallistatin on wound healing is
through inhibition of Wnt signaling by blocking LRP6, we
activated TCF/b-catenin intracellularly via pharmacological
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inhibition of glycogen synthase kinase-3b and subsequent
stabilization of b-catenin using lithium chloride (LiCl).
HDMVECs formed more branches and longer tubes in the
presence of 5mM LiCl versus 5mM NaCl (Figure 6a–c). The
addition of 25mgml 1 purified kallistatin was unable to
significantly attenuate HDMVEC tube formation induced by
5mM LiCl (Figure 6a–c). Consistently, the same concentration
of kallistatin, although able to reduce Wnt3a-induced TCF/b-
catenin-driven transcription and tube formation (Figure 5a–c
and f), was unable to decrease TCF/b-catenin-driven transcrip-
tion induced by LiCl (Figure 6d).
To test whether or not lithium has the capacity to rescue the
wound-healing delay associated with kallistatin overexpres-
sion, wounded mice were treated topically with 20mM LiCl in
DMEM, applied directly to the wounds, a dose previously
shown to activate Wnt signaling in BAT-gal mice in vivo
(Fathke et al., 2006), twice daily for the first 7 days of wound
healing, followed by once daily for days 8–10 of wound
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Figure 6. Lithium attenuates the antiangiogenic and anti-Wnt effects of kallistatin (KS). (a) Tube formation assay with human dermal microvascular endothelial
cells (HDMVECs). (b) Total branch points, n¼ 3. (c) Total tube length, n¼ 3. (d) TCF/b-catenin transcriptional activity in HDMVECs. NS, not significant.
(e) X-gal staining showing Wnt activation in day 7 wounds of Wnt reporter mice in response to NaCl or LiCl topical treatments. (f) Quantification of
Wnt-reporter X-gal activity. (g) CD31þ cells in day 7 wound beds after topical treatments. (h) Quantification of CD31þ cells, day 7 wound beds.
AU, arbitrary fluorescence units. (i) Overall skin wound-healing rate expressed by wound area, N¼ 7–10 age-matched male mice, n¼ 5 or 45 in all analysis
with multiple sections/tissues per analysis. Mean±SEM, *Po0.05, **Po0.01, ***Po0.001, analysis of variance and Tukey’s post hoc significance analysis
performed. Scale bar (e, g)¼ 50mm.
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healing. BAT-gal  KS mice treated with topical LiCl showed
a robust increase in the numbers of cells with activated Wnt
signaling, which were associated with CD31þ areas in the
wound, compared with BAT-gal  KS mice treated with
topical NaCl (Figure 6e and f). The LiCl treatment of KS-TG
mice increased the endothelial cell density in wound beds
significantly compared with KS-TG mice treated with 20mM
NaCl DMEM (Figure 6g and h). As a consequence, topical LiCl
treatment significantly rescued wound repair in KS-TG mice
(Figure 6i).
DISCUSSION
Our study establishes that increased circulating levels of an
abundant, endogenous antiangiogenic serpin in patients with
diabetic microvascular complications contribute to impaired
skin function and wound repair. Kallistatin is secreted by nearly
every cell type in vivo (Chao et al., 1996); yet, its roles in
modulating the structure and physiology of many organs are not
fully understood. Kallistatin was originally identified as a
specific-binding protein and inhibitor of tissue kallikrein (Chao
et al., 1986). Kallistatin is a heparin-binding protein (Chen et al.,
2001) and is expressed in a wide array of tissues and cell types,
including endothelium, salivary glands, and immune cells (Chao
et al., 1996; Wolf et al., 1999). This pattern of expression and
secretion, as well as its characterization as an inhibitor of
angiogenesis, strongly suggests that kallistatin is involved in the
regulation of vascular function and remodeling in skin.
The causes of systemic elevation of kallistatin in diabetic
patients with microvascular complications are not yet known.
It may be due to increased secretion and/or decreased
reuptake by the liver, as the liver has been shown to be the
major recycler of the kallistatin–kallikrein complex from the
circulation (Xiong et al., 1992). We demonstrated in cell
culture that high glucose treatment upregulates kallistatin
expression in HepG2 cells, a cell line derived from human
liver, but did not find evidence that endogenous mouse
kallistatin is elevated in early diabetes in 3-month-old
Ins2akita mice (Supplementary Figure S3 online).
Diabetic patients with retinal and renal complications are at
higher risks of neuropathy and cardiovascular disease and are
more likely to develop foot ulcers and require lower limb
amputations (Monteiro-Soares et al., 2012). Here, we show
that transgenic elevation of human kallistatin levels in mice
affected the ultimate structure and histology of the skin, with
resting skin being thinner in the PA layer, having reduced skin
microvascular density and less hair follicles—features of
human lower limb skin in patients with diabetes and/or
peripheral vascular disease. Although thickening of some parts
of the skin may occur in diabetic patients, such as with
acanthosis nigricans and with diabetic pseudoscleroderma
(Kostler et al., 2005), high levels of kallistatin may
contribute to what is also often seen in diabetic skin—
thinning of the PA layer that harbors the subcutaneous fat
and blood vessels (Petrofsky et al., 2008). As the PA layer loses
structural integrity and becomes thinner, there may be hair
loss, reduced capillary return, neuropathy, ulceration, and
gangrene—signs of tissue damage that precede lower limb
amputation (Hoyt, 2004; Petrofsky et al., 2008). Recent studies
elucidated the cross talk between adipocyte precursor cells,
epithelial stem cells, and hair-follicle cycling (Festa et al.,
2011; Schmidt and Horsley, 2012). Through kallistatin’s
inhibition of Wnt/b-catenin signaling within hair follicles
and endothelial cells, KS-TG mice likely possess defective
crosstalk between hair follicles and adipose tissue. At one
level, the decreased hair-follicle units likely result in less
stimulation of adipose tissue within the PA layer of the mice.
Furthermore, the decreased microvascular density within the
PA layer likely results in less support for adipocyte precursors,
thus disabling the crosstalk between hair follicles and adipose
tissue in coordinating proper skin structure and function.
Diabetic patients are known to have impaired skin blood
flow and hemodynamic changes upon pressure or injury to the
skin (Petrofsky et al., 2009). We found that overexpression of
kallistatin resulted in an impaired hyperemic response to local
ischemia. KS-TG mice do not develop hyperglycemia, but
they still have impaired local skin hemodynamics, mimicking
the defective hemodynamics present in diabetic skin.
Furthermore, KS-TG mice displayed delayed wound healing,
as well as attenuated wound vegf-a expression and wound
neovascularization.
Taken together, our data suggest that kallistatin is an
endogenous Wnt/b-catenin inhibitor in postnatal murine skin;
Wnt signaling is known to be a significant modulator of
inflammation and angiogenesis (Masckauchan and Kitajewski,
2006; George, 2008). Furthermore, the skin/hair-follicle
phenotypes of KS-TG mice are similar to what was reported
in transgenic mice systemically overexpressing DKK-1, a
potent and specific inhibitor of the canonical Wnt pathway
(Sick et al., 2006).
Our recent study showed that kallistatin inhibits Wnt
signaling by blocking LRP6, an essential coreceptor in the
canonical Wnt pathway (Liu et al., 2013). To confirm that the
impact of kallistatin on wound healing is indeed through the
inhibition of Wnt signaling, we activated Wnt signaling
downstream of LRP6. Lithium, a drug approved by the Food
and Drug Administration to treat mood disorders and known
to increase vegf-a expression (Kaga et al., 2006; Guo et al.,
2009), is a potent activator of canonical Wnt signaling, which
acts by inhibiting glycogen synthase kinase-3b and stabilizing
b-catenin. Because lithium activates b-catenin downstream of
LRP6, and has been shown to rescue vascular defects and
restimulate angiogenesis during development (Griffin et al.,
2011; Curtis and Griffin, 2012) and in the cardiovascular (Kaga
et al., 2006) and central nervous systems (Guo et al., 2009),
we chose LiCl as an agent to bypass the blocking effects of
kallistatin on Wnt signaling in vivo and in vitro. Our results
showed that LiCl attenuated the effects of kallistatin on wound
angiogenesis and wound healing in vivo and dermal endo-
thelial tube formation and branching in vitro. This experiment
provides further evidence supporting that kallistatin causes a
wound healing delay through antagonizing LRP6.
We propose the following model: excessive accumulation
of antiangiogenic serpins, such as kallistatin, inhibits Wnt/b-
catenin signaling, contributing to impaired skin endothelial
function and wound healing defects in diabetic patients.
Activation of Wnt signaling downstream of Wnt receptors in
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the endothelium and hair follicles, in and around wounded
skin, may benefit the treatment of impaired wound healing
in diabetic patients with elevated levels of antiangiogenic
serpins, reducing the overall risk of amputations.
MATERIALS AND METHODS
Human subjects
The study, which adhered to the Declaration of Helsinki Guidelines,
was approved by the University of Oklahoma Health Sciences Center
Institutional Review Board, and written informed consent was
obtained from each subject. History and examination were per-
formed, and clinicians confirmed diabetes-associated vascular com-
plication status before this study. Diabetes-associated complications
were predefined as having at least one of the following complications
of diabetes: history of leg, foot, or toe amputation, retinopathy,
documented myocardial infarction or angina with electrocardiogram
changes and/or positive cardiac imaging study, nephropathy, history
of TIA or stroke, angioplasty, or vascular bypass surgery.
ELISA specific for kallistatin
Kallistatin levels in sera were quantified by ELISA (R&D Systems,
Minneapolis, MN), as previously described (Jenkins et al., 2010). For
mouse kallistatin ELISA, wells were coated with 2.0mgml 1 anti-
mouse SERPINA3C antibody (Sinobiological, Daxing, China)
overnight, and recombinant SERPINA3C standard (Sinobiological)
was used for the standard curve.
Kallistatin-transgenic, diabetic, and Wnt reporter mice
The Institutional Animal Care and Use Committee approved all of the
animal experiments described. The chicken b-actin promoter was
used to drive systemic expression of human kallistatin cDNA, and
cloned into the pTriE 1.1 vector (Novagen, Darmstadt, Germany).
Tissue kallikrein activity assays
Enzymatic activity of endogenous tissue kallikrein was assayed using
the colorimetric substrate S-2266 (Chromogenix, Orangeburg, NY),
which can be specifically cleaved by both mouse and human tissue
kallikrein. Upon cleavage, the colorimetric reaction produced a
yellow color, which was quantified by absorbance at 405-nm
wavelength.
Laser Doppler flowmetry
After anesthesia, the hind legs of the mice were fixed in place using
mild-adhesive tape, and the laser Doppler probe was fixed firmly to
the skin to measure perfusion units using the Perimed PeriFlux System
5000 (Perimed, Stockholm, Sweden).
Skin wound healing assay
Clippers were used on dorsal surface of anesthetized mice to remove
hair but retain hair follicles. Standardized circular wounds were made
with biopsy punches, and the Image J software (National Institutes of
Health) was used to trace wound areas and quantify the pixels within
the wound.
Visualization of the transcriptional activity of b-catenin in vivo
Skin and wounds from BAT-gal transgenic mice were stained with
5-bromo-4-chloro-3-indolyl b-D-galactopyranoside according to
the manufacturer’s instructions (Sigma, St Louis, MO).
Dermal microvascular endothelial cell culture and tube
formation assay
Primary human dermal microvascular cells were obtained from ATCC
(Manassas, VA). The cells were seeded on BD matrigel extracellular
matrix mix at a density of 100,000 cells per well in the presence of
WCM or LCM as control or 5mM LiCl in microvascular growth
medium (5mM NaCl as control) and 25mgml 1 purified His-tagged
kallistatin (or 25mgml 1 BSA as control), and were incubated at
37 1C. Twelve hours post seeding, the tube lengths and branching
were imaged under the microscope and quantified to reflect angio-
genesis in vitro.
Topical application of LiCl during in vivo wound healing
During wound healing, sterile 20mM NaCl or 20mM LiCl in serum-
free DMEM was applied topically to open wounds of single-housed
mice (500ml gently ejected from sterile pipette tips under biosafety
hood) twice daily to directly bathe the wounds from days 0 to 7, and
once a day from days 7 to 10. Thereafter, the wounds were allowed to
heal spontaneously.
Statistics
One-way analysis of variance for continuous variables was used with
a Tukey’s honest significant difference post hoc test for differences
between two groups when analysis of variance P-value was o0.05.
For animal studies involving two groups, a two-tailed t-test was
performed with Po0.05 considered significant.
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